Coronary Heart Disease (CHD) Diagnostic Imaging Devices Market By Product (X-ray and Coronary Angiography Systems; Computed Tomography Systems; Nuclear Imaging Systems; Cardiac Magnetic Resonance Imaging Systems; Stress Echocardiography Systems; Intravascular Imaging Systems; Coronary Imaging Software; Intravascular Imaging Catheters and Consumables); By Application (Coronary Artery Disease Diagnosis, Coronary Plaque and Stenosis Assessment, Myocardial Ischemia and Perfusion Assessment, Acute Coronary Syndrome and Myocardial Infarction Evaluation, Coronary Risk Stratification, PCI Planning and Procedural Guidance, CABG Planning, Post-PCI and Post-CABG Evaluation); By End User (Hospitals, Cardiac Catheterization Laboratories, Diagnostic Imaging Centers, Cardiology Clinics, Ambulatory Surgical Centers, Academic and Research Institutions); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Coronary Heart Disease Diagnostic Imaging Devices Market: Imaging Moves Deeper Into the Coronary Care Pathway

The Global Coronary Heart Disease (CHD) Diagnostic Imaging Devices Market is projected to grow at a CAGR of 7.3%, rising from USD 6.97 billion in 2025 to USD 11.42 billion by 2032, according to Strategic Market Research.

 

The market spans the full coronary diagnostic pathway, from noninvasive assessment of suspected disease to image-guided evaluation during intervention. It includes coronary CT angiography and calcium-scoring CT, stress echocardiography, SPECT and PET myocardial perfusion imaging, cardiac MRI, invasive coronary angiography, intravascular ultrasound, optical coherence tomography, and software used for FFRCT and plaque analysis. These technologies help physicians assess coronary anatomy, blood flow, plaque burden, ischemia, and lesion severity before deciding whether a patient requires medical management, further testing, PCI, or bypass surgery.

 

Several revenue models operate within this market. CT, PET, SPECT, MRI, echocardiography, and angiography systems generate capital-equipment, software, maintenance, and replacement-cycle revenue. IVUS and OCT add recurring demand through single-use imaging catheters used during PCI. Coronary-analysis platforms introduce licensing, cloud-processing, subscription, and per-case revenue. Market performance is therefore better assessed through installed systems, procedure volumes, software utilization, service contracts, and consumable demand rather than through one combined device-unit figure.

 

The clinical addressable population remains substantial. Approximately 20.5 million U.S. adults aged 20 or older had coronary heart disease based on 2017–2020 estimates. Globally, the 2021 Global Burden of Disease assessment estimated around 254.3 million prevalent ischemic heart disease cases, 31.9 million incident cases, and nearly 8.99 million deaths. The American Heart Association reported 349,470 U.S. deaths with coronary heart disease as the underlying cause in 2023, while the CDC estimates approximately 805,000 heart attacks occur annually in the United States. These totals represent the wider diagnostic pool rather than annual imaging demand.

 

From Chest Pain Assessment to Intervention Planning

Coronary imaging demand begins before a patient reaches the catheterization laboratory. Noninvasive tests help determine whether symptoms are associated with obstructive coronary disease, whether myocardial blood flow is impaired, and whether invasive evaluation is justified. The selected modality depends on clinical risk, previous test results, local infrastructure, physician expertise, reimbursement, and whether anatomical or functional information is required.

Current chest-pain guidance supports CCTA or functional stress imaging for selected intermediate- and high-risk patients. Functional options include stress echocardiography, PET or SPECT myocardial perfusion imaging, and cardiac MRI. CCTA may also be used when an earlier stress examination is inconclusive or when clinical suspicion remains high despite a negative result.

CCTA can identify plaque and narrowing, analytical software can estimate whether a lesion restricts blood flow, and invasive angiography can confirm the finding or transition directly into PCI. IVUS or OCT may then guide stent sizing, deployment, and post-procedure assessment. Each modality therefore occupies a different point in the clinical pathway rather than competing for every patient.

 

X-ray and Angiography Retain the Largest Revenue Share

X-ray and angiography systems represented an estimated 26.3% of global market revenue in 2025, equivalent to approximately USD 1.83 billion under the Strategic Market Research model. The segment is projected to reach nearly USD 2.92 billion by 2032, expanding at an estimated CAGR of 6.9%.

X-ray coronary angiography remains the largest revenue-generating product segment because it is the established method for real-time coronary visualization during catheterization and can move directly from diagnostic assessment to PCI. Segment revenue includes angiography-system installations, detector and workstation upgrades, procedural software, maintenance contracts, and equipment replacement across high-volume catheterization laboratories.

Growth is expected to remain steady rather than accelerate sharply because angiography already has a mature hospital installed base. CCTA may reduce unnecessary invasive examinations in selected patients, but angiography remains necessary when a lesion requires direct confirmation, physiological assessment, or immediate intervention.

More than 1 million invasive coronary angiograms are reported annually in the United States. The American Heart Association reported 434,230 U.S. PCI procedures in 2020, while peer-reviewed literature estimates more than 2 million PCI procedures worldwide each year. These procedure volumes support continued utilization of angiography equipment, interventional software, IVUS, OCT, and related cath-lab products.

 

Computed Tomography Records the Fastest Product Growth

Computed tomography accounted for an estimated 19.1% of market revenue in 2025, representing approximately USD 1.33 billion. The segment is forecast to reach around USD 2.26 billion by 2032, registering the fastest product CAGR of approximately 7.9%.

CCTA is gaining adoption as a noninvasive method for evaluating coronary anatomy, plaque burden, and stenosis in patients with chest pain or suspected coronary disease. Its use in emergency and outpatient pathways can help physicians exclude significant coronary disease without sending every patient for catheterization.

CT revenue extends beyond the scanner itself. Hospitals purchase cardiac applications, image-reconstruction tools, injector systems, workstations, service contracts, software upgrades, and training. Each CCTA examination may also generate demand for plaque analysis, FFRCT assessment, cloud processing, and specialist interpretation.

The CCTA subsegment accounted for 118,734 U.S. Medicare procedures in 2022, representing approximately 6.3% of the measured noninvasive coronary imaging procedure mix. This likely understates wider U.S. utilization because many patients undergoing CCTA are younger than the traditional Medicare population.

Heartflow’s updated coronary-analysis platform received FDA clearance in 2025. The software analyzes existing cardiac CT data and provides information on coronary anatomy, plaque, stenosis, and FFRCT. Such platforms allow hospitals to extract additional clinical and commercial value from CCTA without performing a second image acquisition.

 

MRI and Nuclear Imaging Serve High-Value Functional Assessment

Magnetic resonance imaging represented an estimated 17.8% of global revenue in 2025, equivalent to approximately USD 1.24 billion. The segment is projected to reach nearly USD 2.05 billion by 2032, expanding at an estimated CAGR of 7.4%.

Cardiac MRI remains concentrated in specialist hospitals and academic centers, where it supports myocardial perfusion, viability assessment, tissue characterization, and the evaluation of patients whose earlier diagnostic results remain uncertain. Growth is supported by faster acquisition, advanced cardiac software, automated reconstruction, and wider use in complex coronary assessment. High scanner costs, longer examinations, and limited specialist availability continue to restrict broader adoption.

Nuclear imaging, including PET and SPECT myocardial perfusion imaging, accounted for an estimated 13.9% share in 2025, producing approximately USD 0.97 billion in revenue. The segment is forecast to reach around USD 1.57 billion by 2032, advancing at an estimated CAGR of 7.1%.

A peer-reviewed Medicare analysis identified 1,343,519 SPECT myocardial perfusion procedures and 212,106 PET myocardial perfusion procedures in 2022. SPECT represented approximately 71.5% of measured U.S. Medicare noninvasive coronary imaging utilization, while PET accounted for 11.3%. These are procedure shares rather than global revenue shares.

SPECT retains a broad installed base and remains widely available across hospitals and nuclear cardiology departments. PET is gaining commercial relevance through myocardial blood-flow measurement, PET/CT investment, improved image quality, and expanding radiotracer access. Nuclear imaging remains important when physicians require functional evidence of impaired perfusion rather than anatomical evidence alone.

Combined, MRI and nuclear imaging represented approximately 31.7% of the market, or around USD 2.21 billion in 2025. Their combined revenue is projected to reach approximately USD 3.62 billion by 2032.

 

Guidelines Strengthen IVUS and OCT Demand

Intravascular imaging represents one of the clearest recurring-revenue opportunities within the market. IVUS and OCT systems combine reusable imaging platforms with single-use catheters used during PCI.

The 2025 ACC/AHA acute coronary syndromes guideline elevated intravascular imaging guidance for relevant PCI procedures to a Class 1, Level of Evidence A recommendation. The stronger recommendation supports investment in consoles, physician training, catheter inventories, and integration between angiography, physiology, and intravascular imaging.

Adoption is likely to remain strongest in complex lesions, left-main interventions, calcified coronary disease, uncertain angiographic findings, and procedures requiring detailed assessment of vessel dimensions or stent expansion. Wider utilization will depend on reimbursement, catheter cost, procedure time, physician familiarity, and whether hospitals standardize imaging-guided PCI.

 

Hospitals and Outpatient Centers Follow Different Economics

Hospitals remain the principal end-user group because they purchase high-value CT, PET, SPECT, MRI, echocardiography, and angiography systems while also performing invasive procedures. Large cardiovascular centers can support several modalities, advanced analytical software, IVUS and OCT platforms, and high examination volumes.

Cath labs create a different revenue profile from general imaging departments. Angiography systems follow long capital replacement cycles, while IVUS and OCT catheters generate recurring sales linked to procedure volume.

Freestanding imaging centers and cardiology practices contribute mainly through CCTA, stress echocardiography, SPECT, and PET. Their purchasing decisions are more sensitive to reimbursement, referral volume, staffing, shared scanner utilization, and the ability to maintain sufficient throughput.

A peer-reviewed analysis recorded approximately 1.88 million noninvasive coronary imaging procedures billed to U.S. Medicare in 2022, demonstrating a substantial recurring examination base distributed across hospitals, outpatient departments, cardiology practices, and freestanding imaging facilities.

 

North America Maintains the Largest Regional Market

North America held an estimated 39.5% revenue share in 2025, equivalent to approximately USD 2.75 billion. The regional market is projected to reach about USD 4.45 billion by 2032, growing at an estimated CAGR of 7.1%.

The United States accounts for most regional revenue through its extensive CT, PET, SPECT, MRI, echocardiography, and cath-lab infrastructure. Equipment replacement, CCTA expansion, reimbursement for coronary-analysis software, high PCI activity, and increasing IVUS and OCT use support continued growth.

The United States has approximately 20.5 million adults with coronary heart disease, around 805,000 annual heart attacks, more than 1 million invasive coronary angiograms annually, and nearly 1.88 million Medicare noninvasive coronary imaging procedures recorded in 2022.

 

Europe Expands Noninvasive Coronary Imaging

Europe represented an estimated 30.3% of global revenue in 2025, producing approximately USD 2.11 billion. The regional market is forecast to reach nearly USD 3.48 billion by 2032, advancing at an estimated CAGR of 7.4%.

Germany, the United Kingdom, France, Italy, and the Nordic countries support demand through established imaging networks, national cardiac-care programs, and increasing use of CCTA and analytical software. Adoption remains uneven because reimbursement, imaging capacity, waiting times, and capital budgets vary between national health systems.

Greater use of cardiac CT is expected to shift a larger portion of diagnostic expenditure toward noninvasive anatomical imaging, while PET, SPECT, MRI, angiography, and intravascular imaging remain important in specialist cardiovascular centers.

 

Asia-Pacific Registers the Fastest Regional CAGR

Asia-Pacific accounted for approximately 25.7% of global revenue in 2025, equivalent to nearly USD 1.79 billion. The market is projected to reach about USD 2.99 billion by 2032, registering the fastest regional CAGR of approximately 7.6%.

China, Japan, India, South Korea, and Australia are increasing investment in cardiac CT, PET, angiography, and intravascular imaging. Private hospital groups and diagnostic networks are also expanding advanced cardiac imaging capacity in major urban areas.

Growth remains uneven because equipment availability, specialist expertise, radiopharmaceutical supply, reimbursement, and service infrastructure are concentrated in larger hospitals. Smaller facilities continue to depend more heavily on echocardiography, SPECT, or referral-based access.

 

Latin America and the Middle East and Africa Expand Selectively

Latin America generated an estimated USD 0.24 billion in 2025, representing approximately 3.5% of global revenue. The region is projected to reach about USD 0.38 billion by 2032, expanding at an estimated CAGR of 6.5%.

Brazil and Mexico account for much of the regional opportunity through private hospital investment, urban diagnostic centers, and gradual modernization of catheterization and imaging facilities. Public-sector budget limitations, imported-equipment costs, and uneven specialist availability continue to moderate adoption.

The Middle East and Africa represented approximately 1.0% of the market in 2025, equivalent to around USD 0.07 billion. Revenue is projected to reach approximately USD 0.11 billion by 2032, growing at an estimated CAGR of 6.2%.

Saudi Arabia, the United Arab Emirates, and South Africa lead regional investment through tertiary hospitals, private healthcare groups, and national diagnostic-capacity programs. Growth across the wider region remains limited by capital constraints, equipment maintenance requirements, and restricted access to advanced cardiac imaging.

 

Competition Shifts Toward Connected Coronary Imaging Platforms

Competition extends across noninvasive image acquisition, coronary-analysis software, catheterization-laboratory imaging, and procedural guidance. Large imaging manufacturers earn revenue through system installations, applications, upgrades, maintenance, and replacement cycles. Interventional-device suppliers add recurring revenue through IVUS and OCT catheters, while software specialists charge through licensing or per-case analysis.

GE HealthCare competes across CT, nuclear cardiology, echocardiography, angiography, cardiac software, and hospital services. Its Revolution Vibe CT system received FDA clearance in 2025 and subsequently recorded its first global installation. The platform was developed around whole-heart cardiac acquisition and workflow automation intended to increase CCTA capacity. GE HealthCare can connect the system with cardiac applications, reconstruction, service, training, PET, SPECT, and wider hospital infrastructure.

Siemens Healthineers participates through SOMATOM CT, MAGNETOM MRI, SPECT and PET platforms, Artis angiography, and clinical software. Its SOMATOM Pro.Pulse broadens access to dual-source cardiac CT beyond major academic centers. The platform addresses cardiac motion in patients with high or irregular heart rates and provides workflow support for facilities with limited specialist capacity.

Philips competes through echocardiography, CT, angiography, IVUS, coronary physiology, co-registration, and clinical software. The company launched IntraSight Plus in March 2026, combining intravascular imaging, coronary physiology, vessel measurements, and treatment-planning functions within one interventional environment. Philips can generate capital revenue through Azurion angiography systems and recurring revenue from intravascular imaging, physiology products, software, and service agreements.

Canon Medical Systems participates through Aquilion CT and Alphenix angiography systems. The Aquilion ONE/INSIGHT Edition supports whole-heart cardiac imaging, rapid acquisition, and AI-assisted reconstruction. Canon reported that cumulative Alphenix shipments reached 1,000 systems in September 2023, providing an installed base for cardiac applications, upgrades, service contracts, and replacement demand.

Abbott competes through OCT imaging, coronary physiology, Ultreon analytical software, and Dragonfly single-use catheters. The FDA cleared the OPTIS Mobile Next, OPTIS Integrated Next, and Ultreon 3.0 platform in 2026. The system combines OCT, automated vessel assessment, plaque and calcium information, and post-PCI stent evaluation. Abbott earns from platform installations and recurring catheter use.

Boston Scientific competes through the AVVIGO+ Multi-Modality Guidance System, OptiCross IVUS catheters, pressure guidewires, and a wider complex-PCI portfolio. AVVIGO+ integrates IVUS, FFR and DFR physiology, automated lesion assessment, rapid pullback, and tableside control. The company can bundle imaging with lesion-preparation products and other interventional devices in high-volume PCI accounts.

Heartflow operates as a coronary software specialist rather than an equipment manufacturer. Its platform analyzes CCTA datasets acquired on compatible third-party scanners and provides coronary anatomy, plaque, stenosis, and FFRCT information. Its updated coronary-analysis software received FDA clearance in 2025. Heartflow can expand without installing proprietary scanners, but its growth depends on CCTA volume, payer coverage, interoperability, and clinical adoption.

Public disclosures do not provide comparable coronary-specific revenue or market-share figures for these companies. Imaging manufacturers report broader business segments, and shared scanners are used across many clinical indications.

 

Market Constraints

Capital cost remains a major adoption barrier. Advanced CT, PET, MRI, and angiography systems require installation, facility preparation, trained personnel, maintenance support, and enough procedure volume to justify investment. Long equipment lives make annual sales dependent on replacement cycles rather than disease prevalence alone.

Reimbursement can shift procedure volume between modalities. Hospitals may have the technical capability to offer CCTA, PET, cardiac MRI, FFRCT, or plaque analysis but use them selectively when payer rules or authorization requirements create friction.

Workforce availability also limits adoption. Cardiac CT, nuclear imaging, MRI interpretation, and intravascular imaging require specialist expertise. Clinical appropriateness further restricts unnecessary repeat testing, as stable patients do not automatically require annual imaging.

 

Commercial Outlook

The market is projected to add approximately USD 4.45 billion in annual revenue between 2025 and 2032, increasing from USD 6.97 billion to USD 11.42 billion. This represents overall expansion of approximately 63.8% across the forecast period.

X-ray and angiography will retain the largest product position, supported by their central role in catheterization and PCI. CT is expected to register the fastest growth as CCTA becomes more integrated into chest-pain pathways and produces additional software and analytical revenue. MRI and nuclear imaging will retain high-value roles in myocardial perfusion, viability, and functional assessment.

The strongest supplier positions combine capital equipment with recurring revenue. CT systems linked to analytical software, angiography platforms connected to physiology and intravascular imaging, and reusable consoles supported by single-use IVUS or OCT catheters can generate revenue at several points in the coronary care pathway.

 

Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 6.97 Billion
Revenue Forecast in 2032	USD 11.42 Billion
Overall Growth Rate	CAGR of 7.3% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product, By Application, By End User, By Geography
By Product	X-ray and Coronary Angiography Systems; Computed Tomography Systems; Nuclear Imaging Systems; Cardiac Magnetic Resonance Imaging Systems; Stress Echocardiography Systems; Intravascular Imaging Systems; Coronary Imaging Software; Intravascular Imaging Catheters and Consumables
Product Subsegments	Coronary CT Angiography Systems; Coronary Artery Calcium Scoring CT Systems; SPECT Systems; PET and PET/CT Systems; Intravascular Ultrasound Systems; Optical Coherence Tomography Systems; FFRCT Analysis Software; Plaque Quantification and Characterization Software; AI-Assisted Coronary Image Analysis Software
By Application	Coronary Artery Disease Diagnosis; Coronary Plaque and Stenosis Assessment; Myocardial Ischemia and Perfusion Assessment; Acute Coronary Syndrome and Myocardial Infarction Evaluation; Coronary Risk Stratification; PCI Planning and Procedural Guidance; CABG Planning; Post-PCI and Post-CABG Evaluation
By End User	Hospitals; Cardiac Catheterization Laboratories; Diagnostic Imaging Centers; Cardiology Clinics; Ambulatory Surgical Centers; Academic and Research Institutions
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, Mexico, Germany, United Kingdom, France, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Brazil, Argentina, Saudi Arabia, United Arab Emirates, South Africa
Market Drivers	Rising prevalence and earlier detection of coronary artery disease; expanding use of non-invasive coronary CT angiography and functional imaging; growing adoption of AI-assisted image analysis and plaque characterization; increasing PCI volumes and demand for intravascular procedural guidance
Customization Option	Available upon request